Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

PINPOINT: Gaming Technology for SCD Pain (Pinpoint II)

29 de julho de 2022 atualizado por: Klein Buendel, Inc.

PINPOINT: Gaming Technology to Engage Adolescent Sickle Cell Patients in Precision Pain Phase II

Sickle cell disease (SCD) is a common genetic disorder characterized by episodes of pain, yet programs to assist SCD adolescents with better identification and communication about pain are lacking. Research shows that interactive gaming technology can enhance adolescents' learning, and can be especially effective in delivering health-related messages and tools to improve self-care. Pinpoint is an interactive gaming app that will be tested in a Phase II project to determine whether the app assists SCD teens with improving their communication and identification skills for pain self-report.

Visão geral do estudo

Descrição detalhada

Sickle cell disease (SCD) is the most common inherited blood disorder in the U.S. and disproportionately affects African Americans and Hispanics. Approximately, 1,000 U.S. children are born with SCD annually. SCD results from abnormal hemoglobin and causes red blood cells (RBCs) to become misshaped ("sickle-shaped"). Sickled cells can block the flow of blood in small arteries causing tissue and organ damage and other life-threatening comorbidities. SCD complications can be serious and have a significant impact upon well-being and quality of life. Pain is the hallmark symptom associated with SCD, and is the most common clinical problem seen in children and the number one cause of SCD-related hospital admissions. If left untreated, these painful episodes can result in morbidity and mortality. Accurate assessment of pain specifiers (type, frequency, and intensity of pain) can help with ameliorating pain quickly and effectively. Despite children being accurate self-reporters of their pain, strategies which are effective and engaging to assist with pain identification and communication of pain are lacking. In a Phase I SBIR, the investigator's team examined the feasibility and acceptability of a gamified tablet application (Pinpoint) intended to encourage teens to talk about and assess their SCD pain. The Phase I specific aims were : (1) work with an Expert Advisory Board (EAB) of experts to develop a new pain assessment tool (PAT) to engage adolescent SCD patients, improve pain specification by patients, and improve pain management by clinicians; (2) conduct cognitive interviews and focus groups with 13-17 year old SCD patients to guide and refine development of app content, design, and aesthetics to fully develop a functioning prototype; (3) conduct usability testing with 13-17 year old SCD patients to assess functionality, navigation, and satisfaction; (4) conduct cognitive interviews with medical providers to provide input on app content, perceived barriers to use, and its potential for clinical use and integration to inform future implementation; and (5) develop a specifications document to outline the Phase II development plan. Deliverables were met and feasibility was confirmed by the EAB. The proposed Phase II project will (1) develop a fully programmed, interactive Pinpoint app consisting of modules to address pain identification and communication; (2) conduct usability testing of Pinpoint to evaluate the user interface, ease of use, and perceived barriers in order to optimize the app prior to large scale evaluation (n=14); and (3) test the full app with 13-17 year olds with SCD (n=100) using a randomized step wedge design to evaluate changes in (a) knowledge acquisition for communicating about pain and types of pain; (b) the Pain Assessment; (c) SCD general knowledge and self-efficacy; (d) family cohesion; and (e) app usage. Overall, the proposed project has the potential to significantly impact the health of SCD teens by providing important skill acquisition for communicating about and identifying pain. This project is innovative and timely. Pinpoint will be the first app to identify and translate specific pain types for SCD into a gamified app using applied gamification principles.

Tipo de estudo

Intervencional

Inscrição (Real)

48

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Colorado
      • Golden, Colorado, Estados Unidos, 80401
        • Klein Buendel, Inc.
    • Indiana
      • Munster, Indiana, Estados Unidos, 463213963
        • Hilton Publishing Company

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

13 anos a 17 anos (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Be 13-17 years of age
  • Be diagnosed with sickle cell disease
  • Able to read and speak English
  • Able to assent to participate

Exclusion Criteria:

  • Not 13-17 years of age
  • Not diagnosed with sickle cell disease
  • Unable to read and speak English
  • Unable to assent to participate

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Pinpoint App
Tablet and smartphone application.
Tablet and smartphone app with pain assessment and communication education, and pain assessment tool.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Sickle Cell Disease (SCD) Knowledge Acquisition
Prazo: baseline
Communicating about pain & SCD pain knowledge: The primary outcome measure will be developed with an Expert Advisory Board (EAB). Psychometric properties will be evaluated using a 3-step scale development process: (1)domain identification and item generation; (2)content expert validation, and (3)pilot test. The investigative team will generate items using a sorting process that encompasses themes/construct elements noted in the communication and pain identification literature (Step 1). Items will then be subjected to expert validation by the expert advisory board (Step 2), The Lawshe's Content Validity Ratio (CVR) will assess the content expert judgment; a minimum CVR value of 0.49 will be required for retention in the scale. For Step 3, usability testers will be asked to complete the measure to guide initial psychometric evidence and allow for revision of the instrument prior to study launch. Reporting of internal consistency reliability is a necessary part of scale development.
baseline
Sickle Cell Disease (SCD) Knowledge Acquisition
Prazo: 4-weeks
Communicating about pain and SCD pain knowledge: The primary outcome measure will be developed with the study's EAB. Psychometric properties will be evaluated using a 3-step scale development process: (1) domain identification and item generation; (2) content expert validation, and (3) pilot test. The investigative team will generate items using a sorting process that encompasses themes/construct elements noted in the communication and pain identification literature (Step 1). Items will then be subjected to expert validation by the expert advisory board (Step 2), The Lawshe's Content Validity Ratio (CVR) will assess the content expert judgment; a minimum CVR value of 0.49 will be required for retention in the scale. For Step 3, usability testers will be asked to complete the measure to guide initial psychometric evidence and allow for revision of the instrument prior to study launch. Reporting of internal consistency reliability is a necessary part of scale development.
4-weeks
Sickle Cell Disease (SCD) Knowledge Acquisition
Prazo: 8-weeks
Communicating about pain & SCD pain knowledge: The primary outcome measure will be developed with the study's EAB. Psychometric properties will be evaluated using a 3-step scale development process: (1)domain identification and item generation; (2)content expert validation, and (3)pilot test. The investigative team will generate items using a sorting process that encompasses themes/construct elements noted in the communication and pain identification literature (Step 1). Items will then be subjected to expert validation by the expert advisory board (Step 2), The Lawshe's Content Validity Ratio (CVR) will assess the content expert judgment; a minimum CVR value of 0.49 will be required for retention in the scale. For Step 3, usability testers will be asked to complete the measure to guide initial psychometric evidence and allow for revision of the instrument prior to study launch. Reporting of internal consistency reliability is a necessary part of scale development.
8-weeks
Sickle Cell Disease (SCD) Knowledge Acquisition
Prazo: 12-weeks
Communicating about pain & SCD pain knowledge: The primary outcome measure will be developed with the study's EAB. Psychometric properties will be evaluated using a 3-step scale development process: (1) domain identification and item generation; (2) content expert validation, and (3) pilot test. The investigative team will generate items using a sorting process that encompasses themes/construct elements noted in the communication and pain identification literature (Step 1). Items will then be subjected to expert validation by the expert advisory board (Step 2), The Lawshe's Content Validity Ratio (CVR) will assess the content expert judgment; a minimum CVR value of 0.49 will be required for retention in the scale. For Step 3, usability testers will be asked to complete the measure to guide initial psychometric evidence and allow for revision of the instrument prior to study launch. Reporting of internal consistency reliability is a necessary part of scale developmen
12-weeks
Sickle Cell Disease (SCD) Knowledge Acquisition
Prazo: 16-weeks
Communicating about pain & SCD pain knowledge: The primary outcome measure will be developed with the study's EAB. Psychometric properties will be evaluated using a 3-step scale development process: (1)domain identification and item generation; (2)content expert validation, and (3)pilot test. The investigative team will generate items using a sorting process that encompasses themes/construct elements noted in the communication and pain identification literature (Step 1). Items will then be subjected to expert validation by the expert advisory board (Step 2), The Lawshe's Content Validity Ratio (CVR) will assess the content expert judgment; a minimum CVR value of 0.49 will be required for retention in the scale. For Step 3, usability testers will be asked to complete the measure to guide initial psychometric evidence and allow for revision of the instrument prior to study launch. Reporting of internal consistency reliability is a necessary part of scale development.
16-weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
PROMIS® (Patient-Reported Outcomes Measurement Information System)
Prazo: baseline
subset of PROMIS measures: The PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of self-report measures that evaluates physical, mental, and social health in adults and children living with or without chronic conditions. The following PROMIS measures will be administered: Family Relationships, Physical Activity, Physical Stress Experiences, Strength Impact, Pain Behavior, Pain Quality- Sensory, Pain Quality-Affective Pain Interference, Psychological Stress Experiences, and Peer Relationships domains. PROMIS measures are scored on the T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. High scores mean more of the concept being measured. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. This could be a desirable or undesirable outcome, depending upon the concept
baseline
PROMIS® (Patient-Reported Outcomes Measurement Information System)
Prazo: 4-weeks
subset of PROMIS measures: The PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of self-report measures that evaluates physical, mental, and social health in adults and children living with or without chronic conditions. The following PROMIS measures will be administered: Family Relationships, Physical Activity, Physical Stress Experiences, Strength Impact, Pain Behavior, Pain Quality- Sensory, Pain Quality-Affective Pain Interference, Psychological Stress Experiences, and Peer Relationships domains. PROMIS measures are scored on the T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. High scores mean more of the concept being measured. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. This could be a desirable or undesirable outcome, depending upon the concept
4-weeks
PROMIS® (Patient-Reported Outcomes Measurement Information System)
Prazo: 8-weeks
subset of PROMIS measures: The PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of self-report measures that evaluates physical, mental, and social health in adults and children living with or without chronic conditions. The following PROMIS measures will be administered: Family Relationships, Physical Activity, Physical Stress Experiences, Strength Impact, Pain Behavior, Pain Quality- Sensory, Pain Quality-Affective Pain Interference, Psychological Stress Experiences, and Peer Relationships domains. PROMIS measures are scored on the T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. High scores mean more of the concept being measured. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. This could be a desirable or undesirable outcome, depending upon the concept
8-weeks
PROMIS® (Patient-Reported Outcomes Measurement Information System)
Prazo: 12-weeks
subset of PROMIS measures: The PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of self-report measures that evaluates physical, mental, and social health in adults and children living with or without chronic conditions. The following PROMIS measures will be administered: Family Relationships, Physical Activity, Physical Stress Experiences, Strength Impact, Pain Behavior, Pain Quality- Sensory, Pain Quality-Affective Pain Interference, Psychological Stress Experiences, and Peer Relationships domains. PROMIS measures are scored on the T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. High scores mean more of the concept being measured. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. This could be a desirable or undesirable outcome, depending upon the concept
12-weeks
PROMIS® (Patient-Reported Outcomes Measurement Information System)
Prazo: 16-weeks
subset of PROMIS measures: The PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of self-report measures that evaluates physical, mental, and social health in adults and children living with or without chronic conditions. The following PROMIS measures will be administered: Family Relationships, Physical Activity, Physical Stress Experiences, Strength Impact, Pain Behavior, Pain Quality- Sensory, Pain Quality-Affective Pain Interference, Psychological Stress Experiences, and Peer Relationships domains. PROMIS measures are scored on the T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. High scores mean more of the concept being measured. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. This could be a desirable or undesirable outcome, depending upon the concept
16-weeks
SCD Knowledge Quiz
Prazo: baseline
SCD knowledge: The SCD Knowledge Quiz is a reliable 10-item measure developed from the Stepping Up to Adult Care Program. Content areas covered are SCD etiology, clinical manifestations, and medical management. Total scores are calculated by summing all items. Higher scores indicate better knowledge of SCD and its treatment.
baseline
SCD Knowledge Quiz
Prazo: 4-weeks
SCD knowledge: The SCD Knowledge Quiz is a reliable 10-item measure developed from the Stepping Up to Adult Care Program. Content areas covered are SCD etiology, clinical manifestations, and medical management. Total scores are calculated by summing all items. Higher scores indicate better knowledge of SCD and its treatment.
4-weeks
SCD Knowledge Quiz
Prazo: 8-weeks
SCD knowledge: The SCD Knowledge Quiz is a reliable 10-item measure developed from the Stepping Up to Adult Care Program. Content areas covered are SCD etiology, clinical manifestations, and medical management. Total scores are calculated by summing all items. Higher scores indicate better knowledge of SCD and its treatment.
8-weeks
SCD Knowledge Quiz
Prazo: 12-weeks
SCD knowledge: The SCD Knowledge Quiz is a reliable 10-item measure developed from the Stepping Up to Adult Care Program. Content areas covered are SCD etiology, clinical manifestations, and medical management. Total scores are calculated by summing all items. Higher scores indicate better knowledge of SCD and its treatment.
12-weeks
SCD Knowledge Quiz
Prazo: 16-weeks
SCD knowledge: The SCD Knowledge Quiz is a reliable 10-item measure developed from the Stepping Up to Adult Care Program. Content areas covered are SCD etiology, clinical manifestations, and medical management. Total scores are calculated by summing all items. Higher scores indicate better knowledge of SCD and its treatment.
16-weeks
SCD Transition Knowledge Questionnaire
Prazo: baseline
SCD knowledge: The SCD Transition Knowledge Questionnaire is a 25-item measure that assesses SCD knowledge relevant to preparation for transition to adult services. It is designed to assess knowledge in 7 areas: (1) pathophysiology, (2) genetics, (3) physical symptoms, (4) treatment, (5) self-care, (6) psychosocial and developmental issues, and (7) health care delivery. Higher scores indicate better knowledge of SCD and its treatment.
baseline
SCD Transition Knowledge Questionnaire
Prazo: 4-weeks
SCD knowledge: The SCD Transition Knowledge Questionnaire is a 25-item measure that assesses SCD knowledge relevant to preparation for transition to adult services. It is designed to assess knowledge in 7 areas: (1) pathophysiology, (2) genetics, (3) physical symptoms, (4) treatment, (5) self-care, (6) psychosocial and developmental issues, and (7) health care delivery. Higher scores indicate better knowledge of SCD and its treatment.
4-weeks
SCD Transition Knowledge Questionnaire
Prazo: 8-weeks
SCD knowledge: The SCD Transition Knowledge Questionnaire is a 25-item measure that assesses SCD knowledge relevant to preparation for transition to adult services. It is designed to assess knowledge in 7 areas: (1) pathophysiology, (2) genetics, (3) physical symptoms, (4) treatment, (5) self-care, (6) psychosocial and developmental issues, and (7) health care delivery. Higher scores indicate better knowledge of SCD and its treatment.
8-weeks
SCD Transition Knowledge Questionnaire
Prazo: 12-weeks
SCD knowledge: The SCD Transition Knowledge Questionnaire is a 25-item measure that assesses SCD knowledge relevant to preparation for transition to adult services. It is designed to assess knowledge in 7 areas: (1) pathophysiology, (2) genetics, (3) physical symptoms, (4) treatment, (5) self-care, (6) psychosocial and developmental issues, and (7) health care delivery. Higher scores indicate better knowledge of SCD and its treatment.
12-weeks
SCD Transition Knowledge Questionnaire
Prazo: 16-weeks
SCD knowledge: The SCD Transition Knowledge Questionnaire is a 25-item measure that assesses SCD knowledge relevant to preparation for transition to adult services. It is designed to assess knowledge in 7 areas: (1) pathophysiology, (2) genetics, (3) physical symptoms, (4) treatment, (5) self-care, (6) psychosocial and developmental issues, and (7) health care delivery. Higher scores indicate better knowledge of SCD and its treatment.
16-weeks
Sickle Cell Self-efficacy Scale
Prazo: baseline
SCD self-efficacy: This instrument, used to assess self-efficacy in adolescents with SCD, is comprised of 9 questions measuring participants' perceptions of their ability to function on a day-to-day basis and to manage SCD symptoms (e.g., pain). The instrument is reliable and valid for assessing adolescents' self-efficacy for engaging successfully in day-to-day activities despite having SCD. Responses from individual items are summed to give an overall score, with higher scores indicating greater self-efficacy.
baseline
Sickle Cell Self-efficacy Scale
Prazo: 4-weeks
SCD self-efficacy: This instrument, used to assess self-efficacy in adolescents with SCD, is comprised of 9 questions measuring participants' perceptions of their ability to function on a day-to-day basis and to manage SCD symptoms (e.g., pain). The instrument is reliable and valid for assessing adolescents' self-efficacy for engaging successfully in day-to-day activities despite having SCD. Responses from individual items are summed to give an overall score, with higher scores indicating greater self-efficacy.
4-weeks
Sickle Cell Self-efficacy Scale
Prazo: 8-weeks
SCD self-efficacy: This instrument, used to assess self-efficacy in adolescents with SCD, is comprised of 9 questions measuring participants' perceptions of their ability to function on a day-to-day basis and to manage SCD symptoms (e.g., pain). The instrument is reliable and valid for assessing adolescents' self-efficacy for engaging successfully in day-to-day activities despite having SCD. Responses from individual items are summed to give an overall score, with higher scores indicating greater self-efficacy.
8-weeks
Sickle Cell Self-efficacy Scale
Prazo: 12-weeks
SCD self-efficacy: This instrument, used to assess self-efficacy in adolescents with SCD, is comprised of 9 questions measuring participants' perceptions of their ability to function on a day-to-day basis and to manage SCD symptoms (e.g., pain). The instrument is reliable and valid for assessing adolescents' self-efficacy for engaging successfully in day-to-day activities despite having SCD. Responses from individual items are summed to give an overall score, with higher scores indicating greater self-efficacy.
12-weeks
Sickle Cell Self-efficacy Scale
Prazo: 16-weeks
SCD self-efficacy: This instrument, used to assess self-efficacy in adolescents with SCD, is comprised of 9 questions measuring participants' perceptions of their ability to function on a day-to-day basis and to manage SCD symptoms (e.g., pain). The instrument is reliable and valid for assessing adolescents' self-efficacy for engaging successfully in day-to-day activities despite having SCD. Responses from individual items are summed to give an overall score, with higher scores indicating greater self-efficacy.
16-weeks
Adolescent Patient-Provider Interaction Scale
Prazo: baseline
Adolescent patient-provider communication: This 9-item instrument is designed to assess adolescent patient-provider communication and empowerment. Total scores are obtained by summing the Likert-item responses for each question. One item is reverse coded. Higher scores represent better interactions.
baseline
Adolescent Patient-Provider Interaction Scale
Prazo: 4-weeks
Adolescent patient-provider communication: This 9-item instrument is designed to assess adolescent patient-provider communication and empowerment. Total scores are obtained by summing the Likert-item responses for each question. One item is reverse coded. Higher scores represent better interactions.
4-weeks
Adolescent Patient-Provider Interaction Scale
Prazo: 8-weeks
Adolescent patient-provider communication: This 9-item instrument is designed to assess adolescent patient-provider communication and empowerment. Total scores are obtained by summing the Likert-item responses for each question. One item is reverse coded. Higher scores represent better interactions.
8-weeks
Adolescent Patient-Provider Interaction Scale
Prazo: 12-weeks
Adolescent patient-provider communication: This 9-item instrument is designed to assess adolescent patient-provider communication and empowerment. Total scores are obtained by summing the Likert-item responses for each question. One item is reverse coded. Higher scores represent better interactions.
12-weeks
Adolescent Patient-Provider Interaction Scale
Prazo: 16-weeks
Adolescent patient-provider communication: This 9-item instrument is designed to assess adolescent patient-provider communication and empowerment. Total scores are obtained by summing the Likert-item responses for each question. One item is reverse coded. Higher scores represent better interactions.
16-weeks
Family Cohesion scale from the Child Health Questionnaire (CHQ)
Prazo: baseline
Family communication: Family cohesion will be assessed by the single item Family Cohesion scale ("In general, how would you rate your family's ability to get along with one another?") from the Child Health Questionnaire (CHQ), a pediatric QOL survey that has been normed for children age 5-18 years including those with chronic diseases. The option response is on a 5-point Likert scale. Th score is transformed to a 0 -100 scale, with a mean of 50 and standard deviation of 10. Higher scores better functioning.
baseline
Family Cohesion scale from the Child Health Questionnaire (CHQ)
Prazo: 4-weeks
Family communication: Family cohesion will be assessed by the single item Family Cohesion scale ("In general, how would you rate your family's ability to get along with one another?") from the Child Health Questionnaire (CHQ), a pediatric QOL survey that has been normed for children age 5-18 years including those with chronic diseases. The option response is on a 5-point Likert scale. Th score is transformed to a 0 -100 scale, with a mean of 50 and standard deviation of 10. Higher scores better functioning.
4-weeks
Family Cohesion scale from the Child Health Questionnaire (CHQ)
Prazo: 8-weeks
Family communication: Family cohesion will be assessed by the single item Family Cohesion scale ("In general, how would you rate your family's ability to get along with one another?") from the Child Health Questionnaire (CHQ), a pediatric QOL survey that has been normed for children age 5-18 years including those with chronic diseases. The option response is on a 5-point Likert scale. Th score is transformed to a 0 -100 scale, with a mean of 50 and standard deviation of 10. Higher scores better functioning.
8-weeks
Family Cohesion scale from the Child Health Questionnaire (CHQ)
Prazo: 12-weeks
Family communication: Family cohesion will be assessed by the single item Family Cohesion scale ("In general, how would you rate your family's ability to get along with one another?") from the Child Health Questionnaire (CHQ), a pediatric QOL survey that has been normed for children age 5-18 years including those with chronic diseases. The option response is on a 5-point Likert scale. Th score is transformed to a 0 -100 scale, with a mean of 50 and standard deviation of 10. Higher scores better functioning.
12-weeks
Family Cohesion scale from the Child Health Questionnaire (CHQ)
Prazo: 16-weeks
Family communication: Family cohesion will be assessed by the single item Family Cohesion scale ("In general, how would you rate your family's ability to get along with one another?") from the Child Health Questionnaire (CHQ), a pediatric QOL survey that has been normed for children age 5-18 years including those with chronic diseases. The option response is on a 5-point Likert scale. Th score is transformed to a 0 -100 scale, with a mean of 50 and standard deviation of 10. Higher scores better functioning.
16-weeks
System Usability Scale (SUS)
Prazo: 16-weeks
Technology acceptability: The System Usability Scale (SUS) is a reliable tool for measuring the usability of technologies. It consists of a 10-item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100. Though the scores are 0-100, these are not percentages and should be considered only in terms of their percentile ranking. Based on research, a SUS score above a 68 would be considered above average and anything below 68 is below average.
16-weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

19 de setembro de 2018

Conclusão Primária (Real)

30 de junho de 2022

Conclusão do estudo (Real)

30 de junho de 2022

Datas de inscrição no estudo

Enviado pela primeira vez

17 de setembro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de outubro de 2020

Primeira postagem (Real)

8 de outubro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de agosto de 2022

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de julho de 2022

Última verificação

1 de julho de 2021

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 322
  • R44MD010746-02 (Concessão/Contrato do NIH dos EUA)

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Pinpoint app

3
Se inscrever